XML 89 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1

Notes to the consolidated financial statements (Tables)

12 Months Ended

Dec. 31, 2023

Notes to the consolidated financial statements

Schedule of revenue from contract with customers recognized

​

​	​	​	​	​	​	​
​		December 31
​	​	2021		2022		2023
​	​	EUR k	​	EUR k	​	EUR k
Belgium	​				​	​
GSK	​	74,298	​	62,263	​	47,128
Germany	​	​	​	​	​	​
Boehringer Ingelheim	​	26,003	​	—	​	—
Netherlands	​	​	​	​	​	​
Genmab	​	1,770	​	1,787	​	1,197
Switzerland	​	​	​	​	​	​
CRISPR	​	919	​	3,370	​	5,425
Others	​	​	​	​	​	​
Others	​	—	​	—	​	8
Total	​	102,990	​	67,420	​	53,758

Summary of upfront payments and related revenues recognized

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Upfront and milestone payments included

​

​

​

​

​

​

​

Upfront and milestone payments

in contract liabilities at

Revenue recognized from upfront and milestone payments

Customer

​

​

​

December 31, 2022

​

December 31, 2023

​

2021

​

2022

​

2023

​

​

(in k)

​

EUR k

​

EUR k

​

EUR k

GSK

EUR 220,000

102,804

88,715

51,728

42,690

29,089

Boehringer Ingelheim

EUR 30,000

—

—

14,003

—

—

Genmab

USD 10,000 (EUR 8,937) *

3,575

2,383

1,787

1,787

1,192

CRISPR

USD 4,500 (EUR 3,947)*

929

1,582

310

310

770

Total

​

107,308

92,680

67,828

44,787

31,051

Schedule of contract balances

​

​	​	​	​	​
​		December 31,		December 31,
​	​	2022	​	2023
​	​	EUR k	​	EUR k
Trade receivables		6,295		14,326
Contract assets		2,707		2,758
Contract liabilities		107,308		92,680

Schedule of contract liabilities allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at year-end

​

​	​	​	​	​
​	​	Year ended December 31,
​		2022		2023
​	​	EUR k	​	EUR k
Within one year		34,759	​	44,580
More than one year		72,549	​	48,100
Total		107,308	​	92,680

Schedule of cost of sales, selling and distribution expenses, research and development expenses and general and administrative expenses

The cost of sales consists of the following:

​

​	​	​	​	​	​	​
​		2021		2022		2023
​	​	EUR k	​	EUR k	​	EUR k
Personnel		(22,159)		(27,185)	​	(37,734)
Materials		(46,250)		(88,891)	​	(59,641)
Third-party services		(139,975)		(32,331)	​	(9,398)
Maintenance and lease		(2,874)		(2,425)	​	(2,672)
Amortization and depreciation		(3,992)		(6,295)	​	(4,850)
Impairment of equipment		(22,810)		(24,948)	​	(8,085)
Other	​	(135)	​	(1,918)	​	(1,986)
Total		(238,195)		(183,993)	​	(124,366)

Selling and distribution expenses consist of the following:

​

​	​	​	​	​	​	​
​		2021		2022		2023
​	​	EUR k	​	EUR k	​	EUR k
Personnel		(1,369)		(2,029)	​	(3,425)
Maintenance and lease		(1)		(35)	​	(45)
Amortization and depreciation		(86)		(336)	​	(18)
Other		(287)		(417)	​	(424)
Total		(1,743)		(2,817)	​	(3,912)

R&D expenses consist of the following:

​

​	​	​	​	​	​	​
​		2021		2022		2023
​	​	EUR k	​	EUR k	​	EUR k
Materials		(232,292)		(32,982)	​	(19,126)
Personnel		(33,733)		(33,944)	​	(43,267)
Amortization and depreciation		(4,259)		(8,650)	​	(8,539)
Patents and fees to register a legal right		(3,199)		(3,813)	​	(6,666)
Third-party services		(539,786)		20,499	​	(28,587)
Maintenance and lease		(347)		(1,069)	​	(7,287)
Other		(2,291)		(2,591)	​	(2,252)
Total		(815,907)		(62,550)	​	(115,724)

General and administrative expenses include the following:

​

​	​	​	​	​	​	​
​	​	2021	​	2022	​	2023
​		EUR k		EUR k		EUR k
Personnel		(37,393)		(36,765)	​	(28,996)
Maintenance and lease		(4,306)		(5,853)	​	(5,353)
Third-party services		(28,875)		(27,669)	​	(29,920)
Legal and other professional services		(9,230)		(10,394)	​	(10,160)
Amortization and depreciation		(8,895)		(11,360)	​	(13,821)
Other		(11,703)		(12,137)	​	(3,508)
Total		(100,402)		(104,178)	​	(91,758)

Schedule of nature of expenses

The nature of the expenses is as follows:

​	​	​	​	​	​	​
​		2021		2022		2023
​	​	EUR k	​	EUR k	​	EUR k
Personnel		(94,655)		(99,924)		(113,422)
Materials		(278,542)		(121,873)		(78,767)
Third-party services		(708,636)		(39,501)		(67,905)
Maintenance and lease		(7,528)		(9,381)		(15,356)
Amortization and depreciation		(17,232)		(26,641)		(27,229)
Impairment of equipment		(22,810)		(24,948)		(8,085)
Patents and fees to register a legal right		(3,199)		(3,813)		(6,666)
Legal and other professional services		(9,230)		(10,394)		(10,160)
Other		(14,415)		(17,064)		(8,170)
Total		(1,156,247)		(353,539)		(335,760)

Schedule of other operating income

​

​	​	​	​	​	​	​
​	​	2021	​	2022	​	2023
​		EUR k		EUR k		EUR k
Compensation for CMO/Materials transfer	​	—	​	35,393	​	2,429
Reimbursement claim	​	—	​	610	​	860
Sale of equipment	​	—	​	785	​	1,195
Grants and other reimbursements from government agencies and similar bodies	​	66,394	​	440	​	3,566
Other		1,308		704	​	1,101
Total		67,702		37,932	​	9,151

X

- Definition

Disclosure of detailed information about upfront payments and related revenues recognized.

+ References

No definition available.

+ Details

Name:	cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory
Namespace Prefix:	cvac_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2023-01-01
-Paragraph 114
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of expenses by nature. [Refer: Expenses, by nature]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 10
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_DisclosureOfExpensesByNatureExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of other operating expense. [Refer: Other operating income (expense)]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 10
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of other operating income. [Refer: Other operating income (expense)]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 10
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of the transaction price allocated to the remaining performance obligations in contracts with customers.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2023-01-01
-Paragraph 120
-Subparagraph b
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2023-01-01
-Paragraph 118
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	ifrs-full_NotesAndOtherExplanatoryInformationAbstract
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration